Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Tulisokibart · MK-7240, PRA-023

Monoclonal antibody · Antagonist of TL1A (TNFSF15) · developed by Merck &

Phase 3 Most advanced trial

MRK Developer

3 Registered trials

What is Tulisokibart?

Tulisokibart is a humanized monoclonal antibody that binds tumor necrosis factor-like cytokine 1A (TL1A). It is being studied in ulcerative colitis and radiographic axial spondyloarthritis.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: MK-7240, PRA-023
Drug type: Monoclonal antibody
Targets: TL1A (TNFSF15)
Mechanism: Antagonist of TL1A (TNFSF15)
Therapy area: Gastroenterology
Developer: Merck & Co. (MRK)
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 3
UNII: ON09TCS5H3

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT06052059	Phase 3	Ulcerative Colitis	Active not recruiting	MRK
NCT07133633	Phase 2	Radiographic Axial Spondyloarthritis	Recruiting	MRK
NCT07405177	Phase 1	Healthy	Completed	MRK

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Radiographic Axial SpondyloarthritisUlcerative ColitisHealthy

More from Merck &

BCG Live FDA approved Belzutifan FDA approved Berahyaluronidase Alfa FDA approved Berahyaluronidase Alfa and Pembrolizumab FDA approved Enlicitide FDA approved Ensifentrine FDA approved Letermovir FDA approved Pembrolizumab FDA approved Probenecid FDA approved Alimatravir Phase 2 Bomedemstat Phase 2/3 Calderasib Phase 3

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the MRK page.

Follow MRK, the company behind Tulisokibart

See MRK's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

MRK catalysts and pipeline →

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z